Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients

Palladino, Claudia; Briz, Verónica; Policarpo, Sergio Negre; Silveira, Laura Fernández; José, Ma Isabel De; González-Tomé, Ma Isabel; Moreno, David; Leal, Juan; Mellado, M José; Ory, Santiago Jiménez de; Ramos, José Tomás; Muñoz‐Fernández, María Ángeles

doi:10.1097/inf.0b013e3181d285ac

Cited by 7 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Palladino et al . studied 20 HIV‐infected children over a median of 180 weeks and reported sustained antiviral response and immunological improvement …”

Section: Introductionmentioning

confidence: 99%

“…Palladino et al studied 20 HIV-infected children over a median of 180 weeks and reported sustained antiviral response and immunological improvement. 5 We conducted a pharmacoepidemiology study to assess the use and long-term safety of FPV in children in 'real world' clinical settings in Europe. Individual patient data originated from cohorts participating in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC), a network of European cohorts of prospectively observed mother-child pairs and children within EuroCoord (www.eurocoord.net).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe

Judd

Duong

Galli

et al. 2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

PurposeFosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged ≥6 years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European Pregnancy and Paediatric HIV Cohort Collaboration.MethodsRetrospective analysis of individual patient data for all children aged 6–18 years taking the licensed dose of FPV up to 31/12/10. Adverse events (clinical events and absolute neutrophil counts, total cholesterol and triglycerides, and alanine transaminase) were summarised and DAIDS gradings characterised severity.ResultsNinety-two HIV-infected children aged 6–18 years took the licensed dose, comprising 3% of the total number of children in follow-up in participating cohorts. Median age at antiretroviral therapy initiation was 6 years (interquartile range 1–11 years), and median age at start of FPV/r was 15 years (12–17 years). Estimated median time on an FPV-containing regimen was 52 months, with a total of 266.9 patient years of exposure overall. Half (54%) were on an FPV-containing regimen at last follow-up. Rates of grade 3/4 events were generally low for all biochemical toxicity markers, and no serious adverse events considered to be causally related to FPV/r were reported.ConclusionsResults suggest that long-term licensed dose FPV-containing regimens appear to be generally well tolerated with few reported toxicities in HIV-infected children in Europe, although relatively infrequently prescribed. No serious events were reported.

show abstract

“…Palladino et al . studied 20 HIV‐infected children over a median of 180 weeks and reported sustained antiviral response and immunological improvement …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe

Judd

Duong

Galli

et al. 2013

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…We have a follow-up of the HIV-infected children in the CoRISpe database of the Paediatric Units and we have been working with these data obtaining interesting results as it is seen in a great number of our published articles [8,16,33-44]. Moreover, the CoRISpe has been collaborating with different European Cohorts (EPPICC, COHERE and PENTA) for many years.…”

Section: Discussionmentioning

confidence: 98%

“…We have done seven research projects with the data provided by the CoRISpe and/or with the samples supplied by the BioBank. The results of all these projects are available to the paediatricians participating in the CoRISpe with a view to improving the state of health of their patients [8,33-44]. …”

Section: Introductionmentioning

confidence: 99%

A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe)

et al. 2013

View full text Add to dashboard Cite

There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In 2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric HIV Network (CoRISpe) was founded. The CoRISpe is divided into the node 1 and node 2 representing geographically almost the whole territory of Spain. Since 2008 seventy-five hospitals have been participating in the CoRISpe. All the retrospective data of the HIV-infected children have been kept in the CoRISpe since 1995 and prospective data since 2008. In this article we are going to present the notion of CoRISpe, its role, the structure, how the CoRISpe works and the process how a child is transferred from Paediatric to Adults Units.The main objective of the CoRISpe is to contribute to furthering scientific knowledge on paediatric HIV infection by providing demographic, sociopsychological, clinical and laboratory data from HIV-infected paediatric patients. Its aim is to enable high-quality research studies on HIV-infected children.

show abstract

“…Es una sulfamida por lo que se debe usar con precaución en pacientes con alergia a sulfas. Se administra dos veces por día en pacientes pediátricos 46 . Las dosis se muestran en la Tabla 5.…”

Section: Darunavir (Drv)unclassified

Nuevos y viejos anti-retrovirales en pediatría: Nuevas dosis, presentaciones y asociaciones

B¹

2010

Rev. chil. infectol.

View full text Add to dashboard Cite

Of the 25 antiretroviral drugs available in the market, only 16 are allowed for prescription in the pediatric patients. The antiretroviral, pertaining to the first three families, used for two decades, remain valid and are important components of antiretroviral therapy in naive children. We describe doses, presentations and current associations for these drugs in children, and also discuss new co-formulations that will reduce the number of doses, improve tolerance and therefore achieve better adherence of pediatric patients.

show abstract

Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients

Cited by 7 publications

References 7 publications

Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe

Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe

A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe)

Nuevos y viejos anti-retrovirales en pediatría: Nuevas dosis, presentaciones y asociaciones

Contact Info

Product

Resources

About